(Q35769862)

10 August 2017

Discontinuing Pneumocystis jirovecii Pneumonia Prophylaxis in HIV-Infected Patients With a CD4 Cell Count <200 cells/mm3. (English)

1 reference

10 August 2017

1 reference

Pneumocystis jirovecii

object named as

Pneumocystis jirovecii

1 reference

Vaninder K Sidhu

1

1 reference

10 August 2017

Michelle M Foisy

series ordinal

2

1 reference

10 August 2017

Christine A Hughes

series ordinal

3

1 reference

10 August 2017

language of work or name

English

0 references

publication date

10 September 2015

1 reference

Annals of Pharmacotherapy

10 August 2017

1 reference

10 August 2017

49

1 reference

10 August 2017

1343-1348

1 reference

10 August 2017

12

1 reference

Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/µL and virologic suppression: a systematic review

10 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1060028015605113

CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015605113

Virologic and immunologic response to HAART, by age and regimen class

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015605113

Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015605113

Discontinuation of primary and secondary prophylaxis for opportunistic infections in HIV-infected patients who had CD4+ cell count <200 cells/mm(3) but undetectable plasma HIV-1 RNA: an open-label randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015605113

Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015605113

Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015605113

The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015605113

Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015605113

Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015605113

21 January 2018

Identifiers

DOI

10.1177/1060028015605113

1 reference

10 August 2017

1 reference